ITHACA, N.Y. – Widespread implementation of personalized medicine will depend upon identification of clinically relevant biomarkers, cost-effective methods to detect them and a reimbursement strategy that will meet the needs of all stakeholders.
These will be a few of the points raised during a workshop entitled “Implementing Effective and Reimbursable Personalized Medicine” at the upcoming joint annual meeting of the American Association for Clinical Chemistry (AACC) and the American Society for Clinical Laboratory Science (ASCLS). Molecular diagnostics company Rheonix, Inc. will host the workshop, with the goal of addressing many of the varied challenges facing the widespread adoption of personalized medicine.
Richard A. Montagna, Ph.D., senior vice president for scientific affairs at Rheonix, will outline these issues in his presentation, “Technical and Reimbursement Challenges of Personalized Medicine.” He will be joined by Dr. Saeed Jortani, associate professor of pathology and laboratory medicine at the University of Louisville School of Medicine, whose talk, “Pharmacogenomics of Pain Management Drugs,” will provide valuable insight into the practical use of genetic data to more effectively manage and treat pain.
The insight gained from this workshop will provide participants with useful information regarding the identification of clinically relevant biomarkers, their utilization in management of drug therapies, as well as the regulatory and reimbursement hurdles that must be overcome in order to implement widespread adoption.
“In order to reduce health care costs, it is imperative that diagnostic companies, health care professionals, regulatory bodies and payers work together to assure that the benefits of molecular diagnostic technologies can be realized for a broad spectrum of real-life diseases facing patients,” Montagna said. “Furthermore, the power of pharmacogenomics can reduce the cost of health care by assuring that the right drug is given to the right person at the right time, while at the same time avoiding the potential of costly adverse events.”
Montagna, based at the Grand Island, N.Y., location of Rheonix, has more than 30 years of leadership experience and has managed the commercialization of more than 40 biotechnology products, including FDA-regulated diagnostics. He has published 40 scientific papers and holds a number of patents in the biosensor area and is an adjunct professor in the department of biological and environmental engineering at Cornell University. Jortani’s training and experience is in toxicology, clinical chemistry, proteomics and pharmacogenomics. He is a board-certified clinical chemist and a practicing toxicologist, with research interests in proteomics, detection and measurement of drugs, therapeutics and poisons, and the use of pharmacogenomics in pain management and postmortem investigations. He serves on several national organizations in the area of laboratory medicine and on the editorial boards of several scientific journals.
The joint conference is being held in Houston from July 28 through August 1. The workshop will take place on July 30 at 7:00 am in Grand Ballroom D of the Hilton Americas Houston. Rheonix will be exhibiting in booth number 5005.